ライフサイエンスコーパス: immunocompromised patient

1 n and reactivation of a past infection in an immunocompromised patient.

2 analysis of intrahost HSV-1 evolution in an immunocompromised patient.

3 f A. elegans invasive fungal infection in an immunocompromised patient.

4 lgae that may cause serious infection in the immunocompromised patient.

5 but not curative effect of remdesivir in an immunocompromised patient.

6 tropism of norovirus in specimens from four immunocompromised patients.

7 merged as a cause of chronic hepatitis among immunocompromised patients.

8 s (IPA) is one of the major complications in immunocompromised patients.

9 Antibiotic treatment is strongly advised in immunocompromised patients.

10 g life-threatening invasive aspergillosis in immunocompromised patients.

11 sponsible for deadly, invasive infections in immunocompromised patients.

12 e of serious human infections, especially in immunocompromised patients.

13 in a larger cohort including non-hematologic immunocompromised patients.

14 uences, infection can be life threatening in immunocompromised patients.

15 s that causes severe disease in newborns and immunocompromised patients.

16 tunistic pathogens and can pose a threat for immunocompromised patients.

17 y prevalent health problem, especially among immunocompromised patients.

18 rus JC virus, which typically occurs only in immunocompromised patients.

19 enotype 3 may result in chronic hepatitis in immunocompromised patients.

20 iratory disease in infants, the elderly, and immunocompromised patients.

21 fe-threatening syndrome that often occurs in immunocompromised patients.

22 oformans is a significant fungal pathogen of immunocompromised patients.

23 or the evaluation of pulmonary infections in immunocompromised patients.

24 d to life-threatening meningoencephalitis in immunocompromised patients.

25 for the treatment of chronic hepatitis E in immunocompromised patients.

26 viduals and for a severe invasive disease in immunocompromised patients.

27 and sepsis in newborns, pregnant women, and immunocompromised patients.

28 f infectious diseases in transplantation and immunocompromised patients.

29 encephalitis is particularly challenging in immunocompromised patients.

30 enza vaccine immunogenicity is suboptimal in immunocompromised patients.

31 ing cutaneous and subcutaneous infections in immunocompromised patients.

32 pneumonia (Pneumocystis pneumonia [PcP]) in immunocompromised patients.

33 nocardiosis and compared immunocompetent and immunocompromised patients.

34 causes potentially fatal bacteremia in some immunocompromised patients.

35 nd a significant health risk, especially for immunocompromised patients.

36 VZV-infected brains obtained at autopsy from immunocompromised patients.

37 in gravest danger: malnourished children and immunocompromised patients.

38 y among vulnerable populations, particularly immunocompromised patients.

39 y illness in young infants, the elderly, and immunocompromised patients.

40 is an opportunistic pathogen that can infect immunocompromised patients.

41 nd it can cause life-threatening diseases in immunocompromised patients.

42 is uncertainty about their immunogenicity in immunocompromised patients.

43 capable of causing bacteremia and sepsis in immunocompromised patients.

44 devastating human diseases, particularly in immunocompromised patients.

45 hospital-acquired pneumonia and a killer of immunocompromised patients.

46 evious studies on hepatitis A vaccination in immunocompromised patients.

47 us PCR assay by using BAL fluid samples from immunocompromised patients.

48 rtant cause of morbidity and mortality among immunocompromised patients.

49 seudomonas aeruginosa in cystic fibrosis and immunocompromised patients.

50 lly untreatable cryptosporidial infection in immunocompromised patients.

51 nificant cause of morbidity and mortality in immunocompromised patients.

52 rasite of clinical importance, especially in immunocompromised patients.

53 nd Asia that can infect humans, particularly immunocompromised patients.

54 ly skin infections and arthritis in severely immunocompromised patients.

55 care and subspecialty providers who care for immunocompromised patients.

56 a life-threatening infection that occurs in immunocompromised patients.

57 literature review to estimate the HZ risk in immunocompromised patients.

58 ncluding Kaposi's sarcoma, commonly found in immunocompromised patients.

59 patitis E virus (HEV) can chronically infect immunocompromised patients.

60 teritis worldwide and can chronically infect immunocompromised patients.

61 V13-emergent serotypes are more prevalent in immunocompromised patients.

62 monary tuberculosis and the risk of death in immunocompromised patients.

63 nally reported to cause severe infections in immunocompromised patients.

64 hepatitis in healthy individuals as well as immunocompromised patients.

65 e considered in fresh produce selections for immunocompromised patients.

66 life-threatening toxoplasmic encephalitis in immunocompromised patients.

67 nital infection and causes severe disease in immunocompromised patients.

68 for drug-resistant strains, particularly in immunocompromised patients.

69 that causes severe, often fatal pneumonia in immunocompromised patients.

70 fungus recently recognized as a pathogen of immunocompromised patients.

71 monitoring treatment response, especially in immunocompromised patients.

72 for diagnosing LTBI, has reduced accuracy in immunocompromised patients.

73 accurately define the usefulness of IGRAs in immunocompromised patients.

74 ns, and septicemia, in otherwise healthy and immunocompromised patients.

75 ential treatment strategy in both normal and immunocompromised patients.

76 icant cause of morbidity and mortality among immunocompromised patients.

77 eased the detection of reemerging viruses in immunocompromised patients.

78 the predominant airborne fungal pathogen in immunocompromised patients.

79 own their safety in both immunocompetent and immunocompromised patients.

80 trol strategies should recommend vaccinating immunocompromised patients.

81 cause significant morbidity and mortality in immunocompromised patients.

82 y in our most vulnerable pediatric and adult immunocompromised patients.

83 espiratory viral pathogens in this cohort of immunocompromised patients.

84 serious causes of morbidity and mortality in immunocompromised patients.

85 portant cause of disease in hospitalized and immunocompromised patients.

86 n can cause severe pathology in children and immunocompromised patients.

87 es (IMDs) of the lung remain a challenge for immunocompromised patients.

88 onsidered an opportunistic human pathogen in immunocompromised patients.

89 xico, but not in blood or urine samples from immunocompromised patients.

90 ily involves prosthetic joints and occurs in immunocompromised patients.

91 sis (IA) is a life-threatening infection for immunocompromised patients.

92 nates to the CNS causing fatal meningitis in immunocompromised patients.

93 enteric and systemic diseases in normal and immunocompromised patients.

94 eatening invasive infections particularly in immunocompromised patients.

95 cussing the benefits and safety profile with immunocompromised patients.

96 l antifungal vaccine strategies effective in immunocompromised patients.

97 for controlling chronic virus infections in immunocompromised patients.

98 with substantial morbidity and mortality in immunocompromised patients.

99 rapid and accurate identification of IPA in immunocompromised patients.

100 al pathogen that infects cystic fibrosis and immunocompromised patients.

101 isseminated infections that can be lethal in immunocompromised patients.

102 mportant cause of morbidity and mortality in immunocompromised patients.

103 mmon cause of invasive aspergillosis (IA) in immunocompromised patients.

104 on of viruses in both previously healthy and immunocompromised patients.

105 plasmosis or postnatally acquired disease in immunocompromised patients.

106 r longer treatment duration may be needed in immunocompromised patients.

107 igh morbidity and mortality, particularly in immunocompromised patients.

108 amous cell carcinomas (cSCCs) in a subset of immunocompromised patients.

109 ally infected children and severe disease in immunocompromised patients.

110 o serious health consequences in neonatal or immunocompromised patients.

111 ruses (gammaHV) can cause lymphomagenesis in immunocompromised patients.

112 mpact on clinical outcomes in transplant and immunocompromised patients.

113 le of causing severe disease in neonates and immunocompromised patients.

114 t to transplant centers and those caring for immunocompromised patients.

115 cases (5%) involving clinically unstable or immunocompromised patients.

116 of herpes simplex virus (HSV) infections in immunocompromised patients.

117 uconazole (ISA) are increasingly utilized in immunocompromised patients.

118 annually, and are typically associated with immunocompromised patients.

119 , is a risk factor for invasive infection in immunocompromised patients.

120 re to estimate HZ risk in five categories of immunocompromised patients.

121 increased risk of morbidity and mortality in immunocompromised patients.

122 lead to severe complications, especially in immunocompromised patients.

123 mportant opportunistic systematic mycosis in immunocompromised patients.

124 nts of severe opportunistic infections among immunocompromised patients.

125 ns such as pregnant and postpartum women and immunocompromised patients.

126 ar concern, chronic progressive hepatitis in immunocompromised patients.

127 on in kidney transplant recipients and other immunocompromised patients.

128 ribing empiric antibiotic therapy for CAP in immunocompromised patients.

129 i remains an important cause of pneumonia in immunocompromised patients.

130 f norovirus-positive EECs in the other three immunocompromised patients.

131 fungal pathogen that can cause infections in immunocompromised patients.

132 bolic or malignant diseases, particularly in immunocompromised patients.

133 s, particularly affecting critically ill and immunocompromised patients.

134 and disappointing results in the elderly and immunocompromised patients.

135 tly become a significant clinical problem in immunocompromised patients.

136 be an alternative approach, particularly for immunocompromised patients.

137 here were 10,316 (43.0%) immunosuppressed or immunocompromised patients, 4,135 (20.3%) with central l

138 We collected 90 respiratory samples from 87 immunocompromised patients (56 bronchoalveolar lavage an

139 In immunocompromised patients, 64% of infecting serotypes w

140 Of 85 immunocompromised patients, 65 used immunosuppressive dr

141 etent patients were significantly older than immunocompromised patients (73 vs. 48.6 years, p < 0.000

142 Among immunocompromised patients admitted to the ICU with hypo

143 istance to oseltamivir were isolated from an immunocompromised patient after prolonged oseltamivir tr

144 es recommend annual influenza vaccination of immunocompromised patients, although the decision to vac

145 fection with Neoscytalidium dimidiatum in an immunocompromised patient and discuss in vitro susceptib

146 pital policies for safe food preparation for immunocompromised patients and by not serving them highe

147 esponses have been extensively documented in immunocompromised patients and during in utero acquisiti

148 ividuals or a serious, systemic infection in immunocompromised patients and has a global impact.

149 py for human adenovirus (HAdV) infections in immunocompromised patients and healthy individuals with

150 associated with life-threatening diseases in immunocompromised patients and in otherwise healthy indi

151 fungal infection that predominantly affects immunocompromised patients and is uniformly fatal if lef

152 known to induce vasoproliferative tumors in immunocompromised patients and may play a role in the de

153 ngles), while HCMV causes serious disease in immunocompromised patients and neonates.

154 infection is increasingly being reported in immunocompromised patients and particularly organ transp

155 sease in a substantial proportion of non-HIV immunocompromised patients and should prompt careful cli

156 ether these new strains are of risk to other immunocompromised patients and the general population.

157 sent an emerging problem during treatment of immunocompromised patients and those hospitalized with s

158 rogressive mental deterioration in an older, immunocompromised patient, and even though Koch's postul

159 of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability

160 s one of the leading causes of infections in immunocompromised patients, and innate immunity provides

161 and complement fixation, is not impaired in immunocompromised patients, and permits highly reproduci

162 HAstV 1-8, are neuropathic, particularly in immunocompromised patients, and should be considered in

163 use of viral diarrhea worldwide in children, immunocompromised patients, and the elderly.

164 bacterium frequently isolated from infected immunocompromised patients, and the strains are resistan

165 Immunocompromised patients are at risk for more severe o

166 enza pneumonia has not been established, and immunocompromised patients are highly susceptible to eme

167 Immunocompromised patients are more susceptible to recur

168 pre-existing pulmonary lesions, and severely immunocompromised patients are susceptible to develop in

169 The most severely immunocompromised patients are those who have been diagn

170 Immunocompromised patients are vulnerable to severe or c

171 tococcus neoformans, a yeast that can affect immunocompromised patients as an opportunistic pathogen.

172 ety of hospital-acquired acute infections in immunocompromised patients as well as chronic respirator

173 lated bacteria that cause lung infections in immunocompromised patients as well as in patients with g

174 ve vaccine efficacy in infants, the elderly, immunocompromised patients, as well as healthy adults.

175 ryptococcal meningitis has been described in immunocompromised patients, as well as in those for whom

176 Varicella can be lethal to immunocompromised patients, babies, HIV patients and oth

177 cant morbidity and mortality worldwide, with immunocompromised patients being at particularly high ri

178 Plasma mNGS demonstrated higher utility for immunocompromised patients, but given the detection of m

179 ssociated with a variety of complications in immunocompromised patients, but no studies have systemat

180 ntral to the management of CMV infections in immunocompromised patients, but quantitative results cur

181 lity was observed in immunocompetent than in immunocompromised patients, but this could be due to mor

182 Chronic norovirus infection in immunocompromised patients can be severe, and presently

183 This study shows that immunocompromised patients can harbor infectious novel n

184 bacteria across the intestinal epithelium of immunocompromised patients can lead to bacteremia and li

185 HEV reinfection in immunocompromised patients can lead to chronic infection

186 alence, risk factors, and characteristics of immunocompromised patients coming from the community wit

187 Among immunocompromised patients, community-acquired pneumonia

188 rugs for the treatment of HAdV infections in immunocompromised patients continues to be a challenging

189 in infants and an opportunistic infection in immunocompromised patients, Cryptosporidium research has

190 fections, chronic infections may occur among immunocompromised patients (e.g., transplant recipients

191 In immunocompromised patients, EBV causes multiple types of

192 known for its propensity to cause disease in immunocompromised patients, especially transplant recipi

193 Among immunocompromised patients evaluated in this study, prog

194 Immunocompromised patients experience a high incidence o

195 aumannii, which causes serious infections in immunocompromised patients, expresses high-affinity iron

196 or relevance due to the increased numbers of immunocompromised patients, frequently delayed diagnosis

197 Immunocompromised patients generally had a delayed antib

198 Immunocompromised patients had higher NSTI-associated in

199 intravenous acyclovir therapy; in contrast, immunocompromised patients had improved outcomes and wou

200 At presentation, immunocompromised patients had lower systolic blood pres

201 Nonsymptomatic immunocompromised patients had similar VZV-specific immu

202 poietic cell transplant, and among survivors immunocompromised patients have shorter median PICU leng

203 s and treatment of other virus infections in immunocompromised patients; however, extension to subjec

204 For some SCCs, particularly those in immunocompromised patients, human papillomavirus (HPV) m

205 The VOS is highly suggestive for IPA in immunocompromised patients in general.

206 ive way of combating severe viral disease in immunocompromised patients in multiple phase 1 and 2 cli

207 during their storage, and cause mortality in immunocompromised patients in numbers that rival the dea

208 -analysis assesses influenza vaccination for immunocompromised patients in terms of preventing influe

209 (IA) remains a leading cause of mortality in immunocompromised patients, in part due to the difficult

210 sent potentially important considerations in immunocompromised patients, in particular in organ trans

211 decreased sensitivity may be problematic for immunocompromised patients, in whom low levels of HAdV i

212 is an emerging fungal pathogen that infects immunocompromised patients including HIV/AIDS, cancer, a

213 illus fumigatus, which is a major threat for immunocompromised patients, including allogeneic hematop

214 are associated with substantial morbidity in immunocompromised patients, including those with HIV/AID

215 HHV-8 and its clinical disease is highest in immunocompromised patients, including transplant recipie

216 neuraminidase H275Y mutation collected from immunocompromised patients infected with pandemic influe

217 Recurrence of C. difficile infections among immunocompromised patients is also high, with rates up t

218 in immunocompetent individuals, their use in immunocompromised patients is complicated by the develop

219 of developing chronic hepatitis in severely immunocompromised patients is high.

220 major challenge in treating toxoplasmosis in immunocompromised patients is lack of therapeutic agents

221 At presentation, immunocompromised patients may fail to exhibit typical c

222 Immunocompromised patients might require combined and pr

223 associated smooth muscle tumors are found in immunocompromised patients, most commonly HIV/AIDS.

224 ) copies/mL and clinical plasma samples from immunocompromised patients (n = 660) were tested.

225 zed trial conducted among 374 critically ill immunocompromised patients, of whom 317 (84.7%) were rec

226 ble and possible categories are proposed for immunocompromised patients only, except for endemic myco

227 pathogens represent a significant threat to immunocompromised patients or individuals with traumatic

228 These conclusions do not apply to immunocompromised patients or when endocarditis is suspe

229 esting to specific groups of patients (e.g., immunocompromised patients), or providing education to e

230 to first surgical procedure were delayed in immunocompromised patients (P < .001 and P = .001, respe

231 ed antigenemia in HIV-positive than non-HIV, immunocompromised patients (P < 0.001).

232 Human CMV still remains problematic in immunocompromised patients, particularly after solid org

233 nt contributor to morbidity and mortality in immunocompromised patients, particularly in the transpla

234 a major cause of morbidity and mortality in immunocompromised patients, particularly those infected

235 elderly men, pregnant women, young children, immunocompromised patients, patients with preexisting li

236 lation of low CrAg titers with disease in an immunocompromised patient population.

237 We describe the case of an immunocompromised patient, positive for influenza A viru

238 Slowly or nonresolving LD may occur in immunocompromised patients, possibly leading to lung abs

239 e a standard part of care for many groups of immunocompromised patients; recent development of the fi

240 ns following respiratory viral infections in immunocompromised patients remain crucial for reducing t

241 Immunocompromised patients represent an increasing group

242 tinal lymphatic transport of cannabinoids in immunocompromised patients requires caution.

243 clinical pertinence not being established in immunocompromised patients, scarcity of clarity on the o

244 microbial therapy for babesiosis in severely immunocompromised patients should be extended to 6 weeks

245 Immunocompromised patients showed moderate to good serol

246 fungi that cause opportunistic infections in immunocompromised patients since these microbes are not

247 astroenteritis in children, the elderly, and immunocompromised patients; some virus strains have also

248 treatment of adenovirus (HAdV) infections in immunocompromised patients still poses great challenges.

249 This is relevant especially for immunocompromised patients such as LTx-recipients or pat

250 pathogen that causes respiratory illness in immunocompromised patients, such as those with cystic fi

251 biota, as well as the unique epidemiology of immunocompromised patients that renders them a particula

252 The disease impacts most severely immunocompromised patients, the elderly, and children.

253 nce surveillance is highly recommended among immunocompromised patients to manage the clinical syndro

254 A systematic visit in a travel clinic for immunocompromised patients traveling to the tropics ensu

255 s well as the threats of viral infections in immunocompromised patients, underline our efforts to cha

256 a significant cause of disease and death in immunocompromised patients, underscoring the need to und

257 d-glucan determined in 70 serum samples from immunocompromised patients were compared to fungal load

258 Immunocompromised patients were less likely to have been

259 Immunocompromised patients were less likely to have EBV

260 The conditions of immunocompromised patients were mimicked by treating pig

261 Sixty-five fecal samples from 16 immunocompromised patients were retrospectively selected

262 This is particularly true in immunocompromised patients, where the damage to the micr

263 the growing incidence of drug resistance in immunocompromised patients, which stresses the urgency t

264 Here, we describe the fatality of an immunocompromised patient who received the varicella vac

265 be a major cause of death in this population Immunocompromised patients who are recipients of a solid

266 ents have significantly improved outcomes in immunocompromised patients who develop invasive aspergil

267 and active viral infection, particularly in immunocompromised patients who have frequent HHV-6B reac

268 Our study included immunocompromised patients who received 1 or 2 hepatitis

269 adverse events have been reported, mainly in immunocompromised patients who subsequently recovered.

270 Notably, one immunocompromised patient with confirmed SARS-CoV-2 infe

271 ith EORTC/MSG criteria for diagnosing IFD in immunocompromised patients with a high degree of antifun

272 In immunocompromised patients with acute respiratory failur

273 r to be of particular importance in severely immunocompromised patients with advanced neoplastic dise

274 minimum of 6 weeks of antibiotics for highly immunocompromised patients with babesiosis, with no para

275 r early treatment of SARS-CoV-2 infection in immunocompromised patients with blood disorders or after

276 ificantly improved with antiviral therapy in immunocompromised patients with herpes meningitis (P < .

277 Immunocompromised patients with HIV infection, chronic r

278 appears to be effective in the short term in immunocompromised patients with HPV-B19 PRCA.

279 Critically ill immunocompromised patients with hypoxemic acute respirat

280 of noninvasive ventilation in critically ill immunocompromised patients with hypoxemic acute respirat

281 been recommended to decrease mortality among immunocompromised patients with hypoxemic acute respirat

282 Immunocompromised patients with hypoxemic acute respirat

283 The objective was to assess outcomes of immunocompromised patients with hypoxemic acute respirat

284 In immunocompromised patients with hypoxemic acute respirat

285 Immunocompromised patients with influenza had more sever

286 deep-sequence longitudinal samples from four immunocompromised patients with long-term H3N2 influenza

287 There is a scarcity of research on immunocompromised patients with necrotizing soft-tissue

288 The correct management of immunocompromised patients with pneumonia is debated.

289 CTPA studies of 78 consecutive immunocompromised patients with proven/probable IPA were

290 1% of asymptomatic adults, but up to 30% of immunocompromised patients with respiratory disease.

291 asibility of developing an immunotherapy for immunocompromised patients with uncontrolled infections.

292 Practice-compliant manufacturing process, in immunocompromised patients with uncontrolled infections.

293 uenza, patients with RSV were older and more immunocompromised; patients with HMPV were older, had mo

294 at often causes lung and brain infections in immunocompromised patients, with a high fatality rate.

295 s the spectrum of EBV(+)diseases, even among immunocompromised patients, with plasma specimens more i

296 During the period 6-11 October 2009, 4 immunocompromised patients within a hematology-oncology

297 The indication for prophylaxis in immunocompromised patients without HIV is less well defi

298 update on the current knowledge of sepsis in immunocompromised patients without human immunodeficienc

299 45 immunocompromised patients without IPA served as a contr

300 atory infections in children and elderly and immunocompromised patients worldwide.